Another longitudinal study reported that both baseline and longitudinal increases in total plasma aSyn predicted the progression of cognitive decline in individuals at risk for PD, presenting with hyposmia and dopamine transporter (DAT) binding reduction (Wang et al. 2018). This evidence concerns the gene SLC6A3 and Parkinson disease.